Didactics-Uterine Serous Carcinoma

Video Transcription

Video Summary

The presentation highlights advancements in understanding and managing endometrial cancer, especially uterine serous carcinoma, catalyzed by the Cancer Genome Atlas. This study identified four subgroups: pol-E mutant (excellent prognosis), MSI high, copy number high (poor prognosis), and NSMP. With surrogate markers like immunohistochemistry, tumor classification has improved, influencing risk group categorization and treatment protocols. The 2021 ASTRO ESP guidelines introduced molecular information into risk stratification, shifting patients between risk categories based on genetic markers like P53 and ER status. New FIGO staging in 2023 further integrates molecular data, refining prognostic accuracy. Uterine carcinosarcoma, with a majority involving P53 mutations, presents additional challenges, particularly for non-Hispanic Black populations at higher risk. Recent studies emphasize the benefits of chemotherapy over whole abdominal irradiation and advocate combined therapy for high-risk groups. The discussion stresses the importance of timely molecular classification in guiding optimal treatment strategies in clinical practice.

Asset Subtitle

Remi Nout
March 2025

Keywords

endometrial cancer

uterine serous carcinoma

Cancer Genome Atlas

molecular classification

treatment protocols